Genetic predisposition to Parkinsonʼs disease: CYP2D6 and HFE in the Faroe Islands

Jónrit Halling, Maria Skaalum Petersen, Philippe Grandjean, Pál Weihe, Kim Brosen

    Research output: Contribution to journalArticlepeer-review

    21 Citations (Scopus)



    To investigate whether the genetic variants of CYP2D6 and HFE are more frequent in Parkinson's disease (PD) patients compared with controls in a population where the prevalence of these variants and PD are increased.

    Blood samples were collected from 79 PD patients and 154 controls in the Faroe Islands. Genotyping for the ‘CYP2D6*3, *4, *6 and *9’ alleles and for the C282Y and H63D mutations were performed by real-time polymerase chain reaction before Taqman assessment.

    The frequency of CYP2D6 poor metabolizers among the patients was not higher compared with the frequency found in the control group (χ2 test, P=0.86). The odds ratio was 0.92 (95% confidence interval: 0.44–1.90). Neither was a difference in HFE genotype or allele frequencies found between the patients and the controls, and the C282Y and H63D mutation carrier frequencies did not reveal any difference (χ2 test, P=0.50 and 0.60, respectively).

    This study does not support an association between PD and mutations of the CYP2D6 and HFE genes, although a weak association cannot be excluded. The high frequency of PD in the Faroes is most likely the result of interactions between multiple genetic and environmental factors, still to be identified.
    Original languageEnglish
    Pages (from-to)209-212
    Number of pages3
    JournalPharmacogenetics and Genomics
    Issue number3
    Publication statusPublished - 2008


    • Parkinson’s disease
    • Faroe Islands
    • CYP2D6 polymorphism
    • HFE
    • risk factors


    Dive into the research topics of 'Genetic predisposition to Parkinsonʼs disease: CYP2D6 and HFE in the Faroe Islands'. Together they form a unique fingerprint.

    Cite this